1246091-48-4Relevant academic research and scientific papers
MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY
-
Page/Page column 42, (2021/08/06)
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra1, Ra2, R
MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY
-
Page/Page column 36-37, (2021/09/17)
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra1, Ra2, Ra3, Ra4, Ra5, Ra6, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.
MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY
-
Page/Page column 67, (2020/12/30)
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, R
HETEROARYL DERIVATIVES OF FORMULA (I) AS ATF4 INHIBITORS
-
Page/Page column 100-101, (2019/10/29)
The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein A, C, D, L2, L3, R1, R2, R3, R4, R 5, R6, z2, z4, z5, and z6 are as defined herein; or salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
